Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma - Episode 9

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

December 5, 2023

Ulka Vaishampayan, MD, Alan Tan, MD, Laurence Albiges, MD, PhD, Neeraj Agarwal, MD, Matthew T. Campbell, MD, MS, Benjamin Maughan, MD, PharmD

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

EP. 1: Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

EP. 2: Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

EP. 3: Imaging and Staging Considerations in Renal Cell Carcinoma

EP. 4: Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

EP. 5: Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

EP. 6: Comparing Treatment Combinations in Renal Cell Carcinoma

EP. 7: Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

EP. 8: Sequencing and Second-Line Therapy in RCC: Patient Scenario

Now Viewing

EP. 9: Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

EP. 10: Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

EP. 11: Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

EP. 12: Triple Combination Therapies in RCC: Clinical Trial Insights

EP. 13: Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment